Cytokine release syndrome‐associated encephalopathy in patients with COVID‐19

European Journal of Neurology, 2021 - Wiley Online Library
Background and purpose Neurological manifestations in coronavirus disease (COVID)‐
2019 may adversely affect clinical outcomes. Severe COVID‐19 and uremia are risk factors …
被引用次数：164 相关文章

Cytokine Release Syndrome-Associated Encephalopathy in Patients with COVID-19

P Perrin, N Collongues, S Baloglu, D Bedo, X Bassand… - 2020 - preprints.org
Severe disease and uremia are risk factors for neurological complications of coronavirus
disease-2019 (COVID-19). An in-depth analysis of a case series was conducted to describe …
[PDF] archive.org

[PDF][PDF] Cytokine Release Syndrome-Associated Encephalopathy in Patients with COVID-19

2020 - scholar.archive.org
Severe disease and uremia are risk factors for neurological complications of coronavirus
disease-2019 (COVID-19). An in-depth analysis of a case series was conducted to describe …

Cytokine release syndrome-associated encephalopathy in patients with COVID-19.

P Perrin, N Collongues, S Baloglu, D Bedo… - European Journal of …, 2020 - europepmc.org
Background and purpose Neurological manifestations in coronavirus disease (COVID)-2019
may adversely affect clinical outcomes. Severe COVID-19 and uremia are risk factors for …

Cytokine release syndrome-associated encephalopathy in patients with COVID-19

P Perrin, N Collongues, S Baloglu, D Bedo… - European Journal of …, 2020 - hal.science
BACKGROUND AND PURPOSE: Neurological manifestations in coronavirus disease
(COVID)-2019 may adversely affect clinical outcomes. Severe COVID-19 and uremia are …

Cytokine release syndrome-associated encephalopathy in patients with COVID-19

P Perrin, N Collongues, S Baloglu… - European journal …, 2021 - pubmed.ncbi.nlm.nih.gov
Background and purpose Neurological manifestations in coronavirus disease (COVID)-2019
may adversely affect clinical outcomes. Severe COVID-19 and uremia are risk factors for …

Cytokine release syndrome-associated encephalopathy in patients with COVID-19.

P Perrin, N Collongues, S Baloglu, D Bedo, X Bassand… - 2020 - cabidigitallibrary.org
Background and purpose: Neurological manifestations in coronavirus disease (COVID)-
2019 may adversely affect clinical outcomes. Severe COVID-19 and uremia are risk factors …
[HTML] nih.gov

[HTML][HTML] Cytokine release syndrome‐associated encephalopathy in patients with COVID‐19

P Perrin, N Collongues, S Baloglu, D Bedo… - European Journal of …, 2021 - ncbi.nlm.nih.gov
Background and purpose Neurological manifestations in coronavirus disease (COVID)‐
2019 may adversely affect clinical outcomes. Severe COVID‐19 and uremia are risk factors …

Cytokine release syndrome‐associated encephalopathy in patients with COVID‐19.

P Perrin, N Collongues, S Baloglu… - European Journal …, 2021 - search.ebscohost.com
Background and purpose: Neurological manifestations in coronavirus disease (COVID)‐
2019 may adversely affect clinical outcomes. Severe COVID‐19 and uremia are risk factors …

Cytokine release syndrome-associated encephalopathy in patients with COVID-19

P Perrin, N Collongues, S Baloglu… - European journal …, 2021 - pubmed.ncbi.nlm.nih.gov
Background and purpose Neurological manifestations in coronavirus disease (COVID)-2019
may adversely affect clinical outcomes. Severe COVID-19 and uremia are risk factors for …